Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody designed to selectively target and inhibit the complement C5a receptor 1 (C5aR1). By blocking the interaction between C5aR1 and its ligand C5a, Avdoralimab effectively prevents receptor activation, offering a therapeutic strategy for the study of complement-driven inflammatory diseases and solid tumors. This antibody is pivotal for researchers focusing on the role of the complement system in pathology and the therapeutic potential of complement inhibition.
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody designed to selectively target and inhibit the complement C5a receptor 1 (C5aR1). By blocking the interaction between C5aR1 and its ligand C5a, Avdoralimab effectively prevents receptor activation, offering a therapeutic strategy for the study of complement-driven inflammatory diseases and solid tumors. This antibody is pivotal for researchers focusing on the role of the complement system in pathology and the therapeutic potential of complement inhibition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
